Regeneron Pharmaceuticals Announces FDA Approval For Extension Of Dosing Intervals For EYLEA HD Up To Every 20 Weeks For Patients With Wet Age-Related Macular Degeneration, Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has received FDA approval to extend dosing intervals for EYLEA HD up to every 20 weeks for patients with wet age-related macular degeneration and diabetic macular edema, contingent on a successful one-year response. The approval includes updated labeling that reflects 96-week data from the pivotal PULSAR and PHOTON trials, showing sustained efficacy and safety over two years with the new dosing schedule.